Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) , Q2 2025 Preliminary Operating Profit Reaches KRW 242.5B (+234.49% YoY), Corrective Disclosure Issued to Populate Missing Pre-tax and Net Income Figures

Posted on August 6, 2025July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) , Q2 2025 Preliminary Operating Profit Reaches KRW 242.5B (+234.49% YoY), Corrective Disclosure Issued to Populate Missing Pre-tax and Net Income Figures

Source: Financial Supervisory Service DART / 2025-08-06

Disclosure Type: Connection/Consolidated Preliminary Earnings (Correction)

💡 3-Second Summary

Celltrion has submitted a corrective disclosure to populate key financial metrics—such as pre-tax continuing operations income (KRW 52.4B) and net income (KRW 63.3B)—which were previously left blank in its preliminary Q2 2025 earnings announcement on July 21.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • Disclosure Context: This report is a correction of the preliminary Q2 2025 financial figures initially submitted on July 21, 2025. It formally updates the disclosure by filling in the previously blank fields for ‘Pre-tax Income from Continuing Operations’, ‘Net Income’, ‘Net Income Attributable to Controlling Interests’, and their respective changes. The figures for Revenue and Operating Profit remain identical to the initial disclosure.
  • Consolidated Q2 2025 Preliminary Performance (Post-Correction):
    • Revenue: KRW 961,457 million (Up +14.20% QoQ / Up +9.91% YoY)
    • Operating Profit: KRW 242,467 million (Up +62.27% QoQ / Up +234.49% YoY)
    • Pre-tax Income from Continuing Operations (Newly Added): KRW 52,427 million (Down -73.18% QoQ / Down -49.68% YoY)
    • Net Income (Newly Added): KRW 63,300 million (Down -41.57% QoQ / Down -19.31% YoY)
    • Net Income Attributable to Controlling Interests (Newly Added): KRW 61,171 million (Down -43.71% QoQ / Down -21.59% YoY)
  • H1 2025 Cumulative Performance (Post-Correction):
    • Cumulative Revenue: KRW 1,803,369 million (Up +11.89% YoY)
    • Cumulative Operating Profit: KRW 391,888 million (Up +345.71% YoY)
    • Cumulative Net Income (Newly Added): KRW 171,633 million (Up +72.98% YoY)
  • Official Reason for Correction: The reason explicitly stated in the filing is “Correction of Q2 2025 Preliminary Consolidated Financial Earnings (Fair Disclosure).” The official disclosure does not provide any specific explanations regarding the underlying causes of the earnings fluctuations or the calculation of these newly populated metrics.

📈 2. [Professional View: What This Disclosure Means for Investors]

  • Resolving Data Gaps and Enhancing Transparency: With this correction, the data gaps from the initial preliminary announcement have been resolved. Investors now have access to the complete set of bottom-line indicators—including pre-tax income and net income—providing full transparency into Celltrion’s H1 and Q2 consolidated financial performances.
  • Objective Interpretation Required: Q2 revenue (KRW 961.5B, +9.91% YoY) and operating profit (KRW 242.5B, +234.49% YoY) both demonstrate strong year-on-year expansion. Conversely, the newly added Q2 net income (KRW 63.3B) indicates a decrease of 19.31% YoY and 41.57% QoQ. Since the filing does not explain the divergence between operating profit and net income, investors should avoid making speculative assumptions about non-operating items and instead verify the factual details via the upcoming finalized financial report reviewed by external auditors.

📝 Editor’s Comment (by K-STOCK Editor)

“This corrective filing is not a downward revision of existing figures, but rather an update to formally populate the pre-tax income and net income metrics that were left blank in the initial disclosure on July 21. While there is a visible divergence between the strong growth in operating profit and the decline in net income, the official document provides no explanation for the specific causes of these fluctuations. Rather than relying on external speculation, investors should focus on the objective facts and wait for the audited financial statements and upcoming corporate presentations to verify the definitive numbers.”

📢 Disclaimer & Source Information

Source: This content was newly structured and drafted based on the official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Guide: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] HANMI Semiconductor (042700) to Hold Extraordinary Shareholders’ Meeting: Appointing IB Expert ‘VP Jung-Young Kim’ as Director & Expanding into Lifestyle Goods and Art E-Commerce
Next Post: [Disclosure] HPSP (403870) Sets August 22 as Record Date to Finalize Voting Rights for Upcoming Extraordinary General Meeting

Related Posts

[Disclosure] Alteogen (196170) Designated as Investment Warning Stock Due to Share Price Surge; Trading May Be Suspended Upon Further Gains Disclosures
[Disclosure] Celltrion (068270) Amends Share Retirement Details, Confirming 488,977 Common Shares for Retirement and Updating Total Value Disclosures
[Disclosure] Celltrion (068270) Approves Financials with KRW 4.16T Revenue and Confirms KRW 750 Cash Dividend per Common Share at AGM Disclosures
[Disclosure] Celltrion (068270) Clarifies Rumor Regarding ‘KRW 300B Chungnam Plant Construction’… “At MOA Stage, Details Under Discussion” Disclosures
[Disclosure] Alteogen (196170) Updates Media Rumor Clarification on ‘KRW 200B RCPS Issuance & Shinhan Securities’: “Financing Options Active But Details Still Unconfirmed; No Contract Signed” Disclosures
[Disclosure] Samsung Biologics (207940) Extends Nondisclosure Period for 2019 UCB CMO Contract Until Year-End 2031 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme